Prurigo Nodularis

6
Pipeline Programs
4
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
2
3
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 4 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Trevi Therapeutics
Trevi TherapeuticsNEW HAVEN, CT
3 programs
3
Nalbuphine ER TabletsPhase 2/31 trial
nalbuphine HCl ERPhase 2/31 trial
nalbuphine HCl ER tablets 90 mg BIDPhase 2/31 trial
Active Trials
NCT03497975CompletedEst. Feb 2023
NCT02174432CompletedEst. Sep 2017
NCT02174419CompletedEst. Aug 2016
Celldex Therapeutics
2 programs
1
1
barzolvolimabPhase 2Monoclonal Antibody1 trial
CDX-0159Phase 11 trial
Active Trials
NCT04944862Completed24Est. Jul 2023
NCT06366750Active Not Recruiting140Est. Mar 2027
Kiniksa Pharmaceuticals
1 program
1
VixarelimabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT03816891Completed240Est. Aug 2023
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabN/AMonoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Trevi TherapeuticsNalbuphine ER Tablets
Trevi Therapeuticsnalbuphine HCl ER
Trevi Therapeuticsnalbuphine HCl ER tablets 90 mg BID
Celldex Therapeuticsbarzolvolimab
Kiniksa PharmaceuticalsVixarelimab
Celldex TherapeuticsCDX-0159

Clinical Trials (6)

Total enrollment: 404 patients across 6 trials

NCT03497975Trevi TherapeuticsNalbuphine ER Tablets

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

Start: Aug 2018Est. completion: Feb 2023
Phase 2/3Completed
NCT02174432Trevi Therapeuticsnalbuphine HCl ER

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Start: Aug 2015Est. completion: Sep 2017
Phase 2/3Completed
NCT02174419Trevi Therapeuticsnalbuphine HCl ER tablets 90 mg BID

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Start: Mar 2015Est. completion: Aug 2016
Phase 2/3Completed
NCT06366750Celldex Therapeuticsbarzolvolimab

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Start: Apr 2024Est. completion: Mar 2027140 patients
Phase 2Active Not Recruiting
NCT03816891Kiniksa PharmaceuticalsVixarelimab

Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo Nodularis

Start: Mar 2019Est. completion: Aug 2023240 patients
Phase 2Completed
NCT04944862Celldex TherapeuticsCDX-0159

A Study of CDX-0159 in Patients With Prurigo Nodularis

Start: Nov 2021Est. completion: Jul 202324 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space